What is the recommended starting dose and titration schedule for amitriptyline, and what monitoring is required?

Amitriptyline Dosing and Monitoring

Start amitriptyline at 25 mg at bedtime and titrate by 10–25 mg every 2 weeks up to a goal dose of 75–150 mg nightly, with slower titration improving tolerability. 1

Starting Dose

• Initiate at 25 mg at bedtime for most adults in outpatient settings 2
• For elderly, adolescent, or frail patients, start at 10 mg three times daily with 20 mg at bedtime (total 50 mg/day) to minimize anticholinergic adverse effects 3, 2
• In primary care for irritable bowel syndrome, begin at 10 mg once daily and allow patient-led titration up to 30 mg over 3 weeks based on symptoms and tolerability 4, 5
• For cyclic vomiting syndrome prophylaxis, start at 25 mg at bedtime 1

Titration Schedule

• Increase by 10–25 mg increments every 2 weeks until therapeutic effect is achieved, dose-limiting adverse effects occur, or maximum dose is reached 1, 6
• Slow titration (10–25 mg every 2 weeks) is generally better tolerated than rapid escalation 1
• For neuropathic pain, increase by 25 mg every 3–7 days as tolerated 6, 3
• Dose at night to leverage sedative effects and minimize daytime impairment 1

Goal/Therapeutic Dose

• Target 75–150 mg nightly for most indications including cyclic vomiting syndrome prophylaxis and neuropathic pain 1, 6
• For outpatients with depression, 75 mg/day in divided doses is usually satisfactory, increasing to 150 mg/day if necessary 2
• Hospitalized patients may require 100 mg/day initially, gradually increased to 200 mg/day if needed; a small subset may need up to 300 mg/day 2
• For irritable bowel syndrome in primary care, most patients respond to 10–30 mg daily without requiring traditional antidepressant doses 4, 5
• For headache prophylaxis, most patients respond to 10–25 mg daily, with low doses (≤25 mg) being effective and well-tolerated 7

Maintenance Dosing

• Usual maintenance is 50–100 mg per day; in some patients 40 mg/day is sufficient 2
• Once improvement is achieved, reduce to the lowest dose that maintains symptom relief 2
• Continue maintenance therapy for 3 months or longer to reduce relapse risk 2
• Total daily dose may be given as a single bedtime dose during maintenance 2

Monitoring Requirements

Baseline Assessment

• Obtain baseline ECG to assess for QTc prolongation risk, especially in patients with cardiovascular disease 1, 2
• Screen for contraindications: urinary retention, angle-closure glaucoma, increased intraocular pressure, seizure history, cardiovascular disorders 2
• Screen for bipolar disorder risk with detailed psychiatric and family history before initiating treatment 2
• Assess for suicidal ideation at baseline, particularly in patients under 25 years 2, 4

Ongoing Monitoring

• Monitor for anticholinergic adverse effects: dry mouth, constipation, urinary hesitancy, blurred vision, sedation, weight gain 1, 6, 3
• Watch for QTc prolongation on ECG, particularly at higher doses 1
• Observe closely for clinical worsening, suicidality, and behavioral changes during the first few months and at dose changes 2
• In elderly patients, monitor carefully and obtain quantitative serum levels as clinically appropriate due to higher plasma levels from decreased hepatic metabolism 2
• Plasma level monitoring is useful when: noncompliance is suspected, toxic effects are present, drug interactions are suspected, or lack of response occurs despite adequate dosing 8, 2
• Therapeutic plasma concentration range for amitriptyline plus nortriptyline (active metabolite) is approximately 100–250 ng/mL 8

Special Populations

• Elderly patients require lower starting doses (10 mg three times daily plus 20 mg at bedtime) and slower titration due to increased anticholinergic sensitivity and altered pharmacokinetics 6, 3, 2
• Patients with cardiovascular disease require close supervision due to risk of arrhythmias, sinus tachycardia, and conduction delays 2
• Patients receiving thyroid medication or with hyperthyroidism require close supervision as amitriptyline may enhance thyroid response 2
• Avoid in pregnancy unless benefit outweighs risk (Category C); teratogenic effects observed in animal studies at high doses 2

Common Pitfalls

• Avoid rapid titration, which increases adverse effects and discontinuation rates 1, 4
• Do not combine with alcohol or CNS depressants due to potentiation of sedative effects and increased overdose risk 2
• Do not use with MAO inhibitors or within 14 days of discontinuing MAOIs 2
• Recognize that analgesic effects occur at lower doses than antidepressant effects (often 10–75 mg vs. 150–300 mg) and with earlier onset (days to weeks vs. 4–6 weeks) 3, 9, 7
• Amitriptyline has more anticholinergic and antihistaminergic activity than nortriptyline; consider switching to nortriptyline if anticholinergic effects are problematic 1, 6
• Prescribe the smallest quantity consistent with good management to reduce overdose risk 2